1. Home
  2. KAI vs MLYS Comparison

KAI vs MLYS Comparison

Compare KAI & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kadant Inc

KAI

Kadant Inc

HOLD

Current Price

$321.12

Market Cap

3.4B

Sector

Industrials

ML Signal

HOLD

Logo Mineralys Therapeutics Inc.

MLYS

Mineralys Therapeutics Inc.

HOLD

Current Price

$32.72

Market Cap

3.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KAI
MLYS
Founded
1991
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.4B
3.1B
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
KAI
MLYS
Price
$321.12
$32.72
Analyst Decision
Buy
Strong Buy
Analyst Count
2
7
Target Price
$340.00
$47.33
AVG Volume (30 Days)
126.2K
1.2M
Earning Date
02-11-2026
02-11-2026
Dividend Yield
0.41%
N/A
EPS Growth
N/A
N/A
EPS
8.65
N/A
Revenue
$1,024,074,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$10.56
N/A
P/E Ratio
$37.99
N/A
Revenue Growth
N/A
N/A
52 Week Low
$244.87
$8.24
52 Week High
$409.73
$47.65

Technical Indicators

Market Signals
Indicator
KAI
MLYS
Relative Strength Index (RSI) 60.99 41.60
Support Level $310.20 $30.96
Resistance Level $334.50 $34.65
Average True Range (ATR) 11.40 1.86
MACD 1.30 0.05
Stochastic Oscillator 76.70 26.11

Price Performance

Historical Comparison
KAI
MLYS

About KAI Kadant Inc

Kadant Inc. supplies process and engineering equipment for papermaking, recycling, lumber manufacturing, and related industries. The company's three reportable segments are the Flow Control segment which consists of the fluid-handling and doctoring, cleaning, & filtration product lines; the Industrial Processing segment which consists of the wood processing and stock-preparation product lines; and Material handling systems, which provides conveyor-belt equipment for industries such as mining, food processing, and packaging. The company has a geographic presence in the U.S., China, Asia, Germany, Canada, and Others.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

Share on Social Networks: